Immunogenic composition against Campylobacter jejuni

Patent metadata

Field	Value
Publication number	US-10765627-B2
Application number	US-201916438743-A
Country	US
Kind code	B2
Filing date	Jun 12, 2019
Priority date	Sep 21, 2005
Publication date	Sep 8, 2020
Grant date	Sep 8, 2020

Abstract

The inventive subject matter relates to an immunogenic composition against Campylobacter jejuni comprising isolated capsule polysaccharide from selected pathogenic Campylobacter jejuni strains. The inventive subject matter also relates to methods of using the polysaccharide compositions in inducing an anti-C. jejuni immune response.

First claim

What is claimed is:

1. A polysaccharide antigen for inducing an immune response against Campylobacter jejuni , said polysaccharide antigen comprising an isolated Campylobacter jejuni capsule polysaccharide from a Campylobacter jejuni strain linked to form a repeating polysaccharide polymer comprising 2 or more of said capsule polysaccharides, wherein said Campylobacter jejuni strain is selected from the group consisting of: HS4, HS5, HS4/13/64, and HS50, wherein said polysaccharide antigens do not contain Campylobacter jejuni lipooligosaccharide structures associated with Guillain Barré Syndrome, wherein said polysaccharide polymer is conjugated to a protein carrier, wherein the structure of HS4 is →3)-L-β-D-ido-Hep-(1→4)-β-D-GlcNAc-(1→, with non-stoichiometric MeOPN at C-4 of LD-ido-Hep, wherein the structure of HS4/13/64 is [→3)-6d-β-D-ido-Hep-(1→4)-β-D-GlcNAc-(1→] n , with non-stoichiometric MeOPN at C-2 and/or C-7 of 6d-ido-Hep, wherein the number of repeats of a capsule polysaccharide “n” is 1 to 100, and wherein the structure of HS5 is selected from the group consisting of

2. The polysaccharide antigen of claim 1 , wherein the structure of HS50 is selected from the group consisting of [→3)-L-β-D-ido-Hep(1→4)-β-D-Glc-(1→] n , with non-stoichiometric MeOPN at C-4 of LD-ido-Hep, and [→3-6d-β-D-ido-Hep-(1→4)-β-D-Glc-(1→] n , with non-stoichiometric McOPN at C-7 of 6d-ido-Hep; and wherein the number of repeats of a capsule polysaccharide “n” is 1 to 100.

3. The polysaccharide antigen of claim 1 or 2 wherein said protein carrier is CRM 197 .

4. A method of immunizing against C. jejuni strains HS4, HS13, HS4/13/64 and HS50 comprising administering to a subject in need thereof one or more antigens, wherein each of said one or more antigens comprises the polysaccharide antigen of claim 1 or claim 2 .

5. The method of claim 4 wherein said protein carrier is CRM 197 .

6. The method of claim 4 wherein said method further comprises administering one or more adjuvants.

7. The method of claim 6 wherein said adjuvant is selected from the group consisting of LTR192G, aluminum hydroxide, RC529, QS21, oligodeoxynucleotides (ODN), and aluminum phosphate.

8. The method of claim 7 , wherein said oligodeoxynucleotide (ODN) is a CpG-containing oligodeoxynucleotide.

Assignees

• Us Navy

Inventors

• Guerry Patricia
• Monteiro Mario Artur

Classifications

• Y02A50/30

  Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title

• A61K39/105

  Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter · CPC title

• A61K2039/6037

  Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT] · CPC title

• A61K31/715

  Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters · CPC title

• A61K9/0019 Primary

  Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title